Enteric fever, representing a systemic infection caused by *Salmonella enteric* serovar Typhi (*S*. *typhi*) and *Salmonella enterica* serovar Paratyphi (*S. paratyphi*), is a common cause of morbidity in the developing world, particularly in South and South East Asia \[[@R1],[@R2]\]. It is estimated that over 22 million cases and more than 200 000 deaths of typhoid fever occurred in the year 2000, with the majority of disease burden being borne by children and adolescents in South and South--East Asia \[[@R1]\]. Highest incidence has been documented in impoverished, overcrowded areas with poor access to sanitation such as the urban slum areas of North Jakarta (Indonesia), Kolkata (India) and Karachi (Pakistan) with annual incidence rates of blood culture--confirmed enteric fever ranging from 180--494/100 000 among 5--15 year-olds and 140--573/100 000 among those 2--4 years old \[[@R3]\]. However, it is recognized that the assessment of disease burden from Africa remains uncertain, with recent reports suggesting that it may be an increasingly recognized but underreported problem, requiring further prevalence studies \[[@R4]-[@R6]\]. Prevalences ranging from 0% to 4.23% have been reported from Kenya, Africa, in a recent review \[[@R7]\].

Despite the high burden of disease, challenges in the diagnosis and management of enteric remain. Clinical diagnosis of enteric fever is nonspecific and mimics other febrile illnesses like malaria and dengue fever and influenza \[[@R5],[@R6]\]. This is particularly true for children who can present with atypical signs and complications such as neurological dysfunction, nephropathy and cardiac abnormalities \[[@R4],[@R8],[@R9]\] and thus lead the clinician away from a diagnosis of enteric fever. Attempts have been made to develop and validate clinical algorithms \[[@R10],[@R11]\], without becoming mainstream for usage in diagnosis. The lack of availability of the blood cultures, in many small hospitals and community settings in endemic populations is an additional limitation, as is the low yield of the test due to prior antibiotic treatment or sampling issues in young children \[[@R12],[@R13]\]. These factors can contribute to delayed diagnosis and/or inappropriate treatment \[[@R12],[@R14]\].

The emergence of drug resistance and changing patterns of both multi--drug (MDR)(resistant to all three traditional first--line agents: chloramphenicol; ampicillin; and co--trimoxazole) and fluoroquinolone resistant *S*. *typhi* and *S*. *paratyphi* \[[@R12],[@R15]\] has been associated with reported changes in the severity and clinical profile of enteric fever \[[@R6],[@R16]-[@R19]\].Nearly 60% of typhoid fever isolates tested in Kolkata and Karachi and 44% of those in Hue, Vietnam were resistant to nalidixic acid; making these cases less responsive to commonly used second line agents such as ciprofloxacin and other fluoroquinolones \[[@R3],[@R14]\]. This has not only narrowed the therapeutic options in high disease burden countries but has also lead to increased treatment costs, severity of illness, higher rates of complications and higher case fatality rates \[[@R6],[@R14],[@R17],[@R20],[@R21]\].

Although enteric fever is essentially a paediatric disease in South Asia, there is dearth of retrospective and prospective studies done in children with culture proven enteric fever in the global literature \[[@R22]\]. Furthermore, most studies on enteric fever represent hospitalized subjects and the differences in the clinical features and severity of the disease may also differ substantially from those not requiring hospitalization. Hospitalization rates of up to 2--40% among culture--confirmed ambulatory enteric cases were found in five different study sites in Asia \[[@R23]\], but data from those not hospitalized could represent a different disease severity and pattern. Differences in health seeking behavior of hospitalized vs community based subjects as well as differences in access may also limit generalization of available literature on clinical patterns of enteric fever \[[@R6]\].

In addition, reports suggest a considerable influence of age; with some studies documenting increased morbidity and mortality in younger children \[[@R19],[@R20],[@R23]-[@R25]\] while others \[[@R26],[@R27]\] report comparatively better outcomes in this age group. Reports also suggest differences in presentation and outcomes between children and adults \[[@R19],[@R20],[@R28]\].Data from individual studies suggest a difference in clinical spectrum of disease amongst geographical locations in high--income and low and middle--income countries. In a report from an Ethiopian children\'s hospital (1984--1995), intestinal perforation occurred in 27 patients (25%) out of which 10 (37%) died \[[@R29]\]. During a similar time (1982--1995) in Taiwan, only 2/71 cases of intestinal perforation were reported in children \[[@R30]\].Prevalence of co--morbidities such as HIV, differences in antimicrobial resistance patterns, over--the--counter antibiotic availability, substandard antibiotic preparations, lack of pipe--borne portable water supply, health system functionality and health seeking behaviors all weigh in to the differences seen in disease spectrum, complications and mortality across regions.

No comprehensive systematic review exists describing the differences in clinical features of enteric fever and the frequency of its complications by various age groups. Further, the differences in clinical presentation by economic and geographical regions and by drug resistance patterns have not been systematically investigated.

This systematic review assesses the clinical profile of enteric fever across different regions and age groups (children vs adults). We also compare the epidemiology of enteric in hospitalized and community settings and in children infected with multi--drug resistant vs sensitive strains of *S*. *typhi*. Finally we describe the relationship between multidrug resistance patterns and case--fatality rates over time.

METHODS
=======

We searched PubMed for studies limited to Humans (1964 onwards; last searched December 2013), and English language using MeSH and text words as shown in [**Figure 1**](#F1){ref-type="fig"}. We conducted additional parallel searches for the following to ensure comprehensive identification of all relevant reports: a) non--English language studies (title/abstracts screen); b) clinical trials; c) relevant articles were manually retrieved from reference lists and other pertinent studies, known to the authors and not already retrieved from PubMed were included ("author's collection").

![Search methodology. \*Mixed ages, no clinical features or excluded complicated cases on enrollment. †"Others" (1024) includes: Studies on Typhoid carriers (44) Non-typhoid (mostly Rickettsia)/diarrheal diseases/other Salmonella (561) General public health/sanitation (58) Not relevant/other laboratory-based/miscellaneous (112) Reviews, letters, editorials (249). ‡"Others" (n = 20) includes: Non-typhoid(mostly Rickettsia)/diarrheal diseases/other Salmonella (n = 1), General public health/sanitation (n = 1), Not relevant/other laboratory-based/miscellaneous (n = 14), Reviews, letters, editorials (n = 5).](jogh-05-020407-F1){#F1}

All studies indicating documentation of clinical features, based on title and/or abstract, were retrieved in full--text where available ([**Figure 1**](#F1){ref-type="fig"}). Regional break--up of countries was taken from the World Bank list of Economies (updated April 2012) \[[@R31]\].

Inclusion criteria
------------------

We included studies which reported clinical features from diagnosed cases of enteric fever. Diagnosis was based on either a positive culture (blood, bone marrow, other sterile site--stool, urine) or a positive serological diagnostic test (Widal test/Typhi Dot test), as long as the diagnosis was confirmed by culture tests in at least 50% of these cases. Outcome data in children (age as author defined, or 0--15 years) or adults (age as author defined, or 12 years and above) was included if given in disaggregated form. We included clinical trials, vaccine trials, diagnostic studies, only where any clinical features were described provided they met the pre--defined criteria ([**Box 1**](#B1){ref-type="boxed-text"}).

###### Pre-set inclusion criteria

1\. Studies must have clearly documented data on at least one clinical feature (other than drug resistance or mortality)

2\. Studies were included from 1964 onwards as well as articles not indexed in PubMed before that at the time of searching

3\. Number of cases reported on in each study had to be more than 5 (n ≥5)

4\. Studies with cases of only S. typhi were included, unless data was given for both *S. typhi* and *S. paratyphi* in an aggregated form which could not be separated

5\. Studies must include enteric fever of all severity (eg: excluded if only uncomplicated cases were included)

6\. Studies must have at least 50% or more culture positivity (blood, bone marrow, urine or stool) along with serologically positive cases (not included if only diagnosed on clinical basis)

7\. Cases must be in distinct age groups--children or adults

8\. Studies must not be from a certain population subset (eg, all HIV positive, all intestinal perforations)

9\. Studies that were not in English must have adequate, extractable information in the abstract

10\. Studies published from the same hospital/region and during the same time period were considered as duplicate/overlapping data and counted once using the largest reported denominator

Exclusion criteria
------------------

We excluded case reports (as indexed, or those with a sample size ≤5), studies reporting mixed age groups (ie, 2 to 55 years) where disaggregation on age was not stated, with some or all cases diagnosed only on clinical suspicion and reports of selective patient groups (eg, all complicated, or all HIV cases, or all cases presenting with diarrhea). Studies using only a clinical diagnosis or serological diagnostic tests only (Widal test/Typhi Dot test), without culture confirmation were excluded. For studies reporting data for *S*. *typhi* and *S. paratyphi* separately, only data for *S*. *typhi* were extracted; however if studies did not present data separately, data was included as both *S*. *typhi* and *S. paratyphi*.

In addition to baseline characteristics, geographical location, resistance and clinical features, data were also extracted separately where available for different age groups and for multi--drug resistance and sensitive isolates. Clinical features were used as author defined or as a given set of definitions if otherwise undefined (Chart 1 in **Online Supplementary Documentation[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**). For each clinical feature, we extracted the number of patients with the event and the number of patients assessed for the feature. Similar features were grouped together (such as "encephalopathy" and "lethargy" grouped under "altered mental status"); the largest uncombined numerator was used when several similar features were reported in a study.

Statistical methods
-------------------

Data was double entered into Microsoft Access 2007 and tabulated using Microsoft Excel 2007 (Microsoft Corp., Redmond, WA, USA) spreadsheets. Frequency tables of clinical features were calculated also using Microsoft Excel. Further analysis was done using χ^2^--testing for different ages (0--5 years vs 5--10 years; children 0--5 years and 5--10 years vs adults), for economical/geographical regions (Africa vs South Asia); for hospital vs community settings and for MDR strains vs sensitive strains). The level of significance was set at \<0.05and odds ratio (OR) are reported for likelihood of clinical feature between different categories. All analysis was done using OpenEpi \[[@R32]\].

RESULT
======

Included studies
----------------

242 reports were screened out of a total of 4398 articles retrieved with the search strategy (Stage 1). All studies with culture (blood, bone marrow, other sterile site stool, urine) confirmed enteric fever were included, as well as serologically confirmed enteric fever if percentage of culture confirmed cases was more than 50% (Stage 2). Disaggregated age data from these studies, if available, were also extracted assuming a similar proportion of culture--confirmed cases in each age group. Categorization of excluded studies is shown in [**Figure 1**](#F1){ref-type="fig"}.

A total of 180 reports were included for final review. [**Figure 2**](#F2){ref-type="fig"} summarizes the characteristics of included studies (153 primary references and 27 references with overlapping data): 82 studies were on children, 63 on adults and 8 studies provided disaggregated data for adults and children (2 reports from overlapping or potentially overlapping data). Urban, hospital--based, inpatient retrospective studies were predominant. Data for resistance and relapse were uncommonly presented. Studies with only *S.typhi* were 72%, while 28% had representation of both *S. typhi* and *S*. *paratyphi* which could not be separated out. [**Figure 3**](#F3){ref-type="fig"} shows the geographical representation of countries with included studies with the relative contribution of data from different regions. India far outranked other countries, with 46 studies in total (41% of included studies).

![Breakdown of included studies. 8 studies with disaggregated data for Adults and Children are counted only once in Child category, 27 studies had overlapping/duplicate data (Total 180). MD -- multidrug resistance; FQ -- fluoroquinolones.](jogh-05-020407-F2){#F2}

![Map of geographical distribution of included studies.](jogh-05-020407-F3){#F3}

Epidemiology of enteric fever in children vs adults
---------------------------------------------------

Studies in adults and those with data from children in disaggregated age groups were tabulated, from all available settings ([**Table 1**](#T1){ref-type="table"} and Table S1 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**). Fever was universal (97%--100%) and a coated tongue was consistently noted in all children\'s age groups (71%--85% range). Signs and symptoms such as anaemia (71%), leukocytosis (47%), hepatitis (36%) and hepatomegaly (50%) were more common among pre--school children (under 5 years) than in other age groups, while headache and abdominal pain/tenderness was reported to be less common in this age group (14% and 20% respectively). Altered mental status (30%), signs of URTI (22%), leucopenia (57%), abdominal pain/tenderness (70%) were common in school--aged children. Headache (75%), abdominal distension (66%), cough (60%) and pneumonia (19%) were more common in older children aged 10--17 years. In contrast, more adults presented with nausea/vomiting (49%), splenomegaly (39%), GI perforation (5%), and thrombocytopenia (52%). Relative bradycardia, chills/rigors and dehydration were also frequently reported. Toxicity throughout the ages was found to be 26--38%. GI perforation was more common as age increased. Children were infected with MDR strains in 22--25% cases, as compared to more than half of enteric cases in adults which were MDR. Relapse was similar in all ages, but pre--schoolchildren had the highest fatality rates (6%), compared to all other age groups.

###### 

Epidemiology of enteric fever by age (references to studies in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**)

                                      0--5 years (15 studies)\*   5--10 years (8 studies)†   10--17 years (5 studies)‡   Adults ≥12 years (73 studies)§                                                               
  ----------------------------------- --------------------------- -------------------------- --------------------------- -------------------------------- ------- --------- ------- ------- --------- ------- ------- --------
                                      **n**                       **N**                      **%**                       **n**                            **N**   **%**     **n**   **N**   **%**     **n**   **N**   **%**
  **Signs and symptoms--systemic:**                                                                                                                                                                                   
  Fever                               265                         274                        **97**                      194                              194     **100**   39      39      **100**   2287    2337    **98**
  High grade fever                    11                          77                         **14**                                                                                                   111     292     **38**
  Headache                            15                          104                        **14**                      70                               125     **56**    6       8       **75**    1149    1830    **63**
  Toxicity                            169                         492                        **34**                      184                              586     **31**    70      268     **26**    208     543     **38**
  Rash or rose spots                  2                           12                         **17**                      6                                93      **6**     5       84      **6**     75      982     **8**
  Coated tongue                       28                          33                         **85**                      154                              190     **81**    32      45      **71**    490     881     **56**
  **Respiratory and abdominal:**                                                                                                                                                                                      
  Cough                               58                          187                        **31**                      78                               231     **34**    32      53      **60**    595     1459    **41**
  Nausea or vomiting                  61                          193                        **32**                      88                               194     **45**    5       39      **13**    792     1628    **49**
  Diarrhea                            286                         665                        **43**                      173                              752     **23**    94      276     **34**    1118    2407    **46**
  Constipation                        52                          439                        **12**                      177                              752     **24**    31      276     **11**    382     1570    **24**
  Hepatomegaly                        261                         526                        **50**                      276                              630     **44**    93      245     **38**    555     1903    **29**
  Splenomegaly                        165                         635                        **26**                      228                              789     **29**    71      290     **24**    883     2278    **39**
  Abdominal pain or tenderness        29                          143                        **20**                      136                              194     **70**    19      39      **49**    981     1827    **54**
  Abdominal distention or ileus       24                          131                        **18**                      90                               190     **47**    35      53      **66**    139     831     **17**
  **Laboratory features:**                                                                                                                                                                                            
  Anaemia (Hb \<12 g/dl)              50                          70                         **71**                      21                               31      **68**                              487     1687    **29**
  Leukopenia (\<5 × 10^3^/µL)         17                          81                         **21**                      71                               125     **57**                              800     2248    **36**
  Leukocytosis (\>15 × 10^3^/µL)      198                         417                        **47**                      91                               558     **16**    27      237     **11**    32      238     **13**
  **Complications:**                                                                                                                                                                                                  
  Shock or hypotension                3                           63                         **5**                       9                                97      **9**     0       36      **0**     145     1559    **9**
  Altered mental status               27                          197                        **14**                      86                               287     **30**    4       75      **5**     972     3339    **29**
  Pneumonia or chest signs            28                          194                        **14**                      57                               318     **18**    15      81      **19**    205     1921    **11**
  GI bleeding                         8                           158                        **5**                       11                               189     **6**     6       75      **8**     177     2557    **7**
  GI perforation                      1                           127                        **1**                       5                                194     **3**     0       31      **0**     110     2183    **5**
  **Outcome:**                                                                                                                                                                                                        
  Relapse                             18                          399                        **5**                       29                               614     **5**     14      273     **5**     66      1516    **4**
  Death                               38                          656                        **6**                       10                               751     **1**     1       75      **1**     197     4698    **4**

n -- number with feature, N -- number assessed

\*Includes studies with data for under 1, under 2, under 3 and under 4 year--olds.

†Includes studies with data for 5 to 12, 5 to 13 and 6 to 12 year--olds.

‡Includes studies with data for 10 to 14, 10 to 15 and 10 to 17 year--olds.

§Includes a large number of adolescents, since author definition of adults was very varied (eg: 12 years and above, 15--59 years).

In comparing children 0--5 years with children aged 5--10 years, different features were found to be more likely to occur (Table S2 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**), and after pooling data for children under 10 years compared to adults (author defined ages or aged 12 and above), the features more likely to occur in children are shown in and Table S3 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**.

Regional spectrum of enteric fever in children
----------------------------------------------

Data was provided from above referenced studies on children as well as age disaggregated studies--in total 90 studies ([**Table 2**](#T2){ref-type="table"} and Tables S1 and S2 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**). In almost all regions, 40% of enteric cases presented after receiving prior antibiotics. MDR enteric fever was highest in the Middle East & North Africa from 3 studies, followed by South Asia. Fluoroquinolone resistance was reported rarely in almost all regions. The most common feature globally was fever. Other common features were anaemia (highest in South Asia), hepatomegaly (commonest in East Asia & Pacific), and coated tongue. Toxicity and relative bradycardia was seen highest in Sub Saharan Africa. Diarrhea was more common than constipation, except in East Asia/Pacific. Sub Saharan Africa and Middle East/North Africa had a higher occurrence of abdominal distension and ileus, as well as GI perforation (6%). High income countries reported more weakness/malaise, rose spots and an intermittent pattern of fever. Relapse was consistently low: 2--9% and case--fatality rate ranged from 1--6%, highest in Sub Saharan Africa and North Africa/Middle East regions.

###### 

Spectrum of enteric fever by economic and geographical regions (references to studies in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**)

                                      High income countries (17 studies)   Europe & Central Asia (4 studies)   Sub--Saharan Africa (12 studies)   Middle East & N. Africa (3 studies)   South Asia (41 studies)   East. Asia & Pacific (11 studies)                                                                                               
  ----------------------------------- ------------------------------------ ----------------------------------- ---------------------------------- ------------------------------------- ------------------------- ----------------------------------- ------- ------- -------- ------- ------- --------- ------- ------- -------- ------- ------- --------
                                      **N**                                **N**                               **%**                              **n**                                 **N**                     **%**                               **n**   **N**   **%**    **n**   **N**   **%**     **N**   **N**   **%**    **n**   **N**   **%**
  **Demographics/history:**                                                                                                                                                                                                                                                                                                                       
  Blood/bone marrow isolates          540                                  710                                 **76**                             122                                   131                       **93**                              1069    1382    **77**   250     281     **89**    5280    5736    **92**   891     1012    **88**
  Pre--treatment antibiotics          10                                   13                                  **77**                             6                                     80                        **8**                               15      35      **43**                             1804    3152    **57**   255     570     **45**
  Duration of illness ≤1 week         68                                   161                                 **42**                                                                                                                                 343     574     **60**   92      150     **61**    879     2013    **44**   203     325     **62**
  Multi--drug resistant isolates      10                                   288                                 **3**                              0                                     72                        **0**                               0       120     **0**    60      60      **100**   1885    4214    **45**   150     459     **33**
  Fluoroquinolone resistance          0                                    12                                  **0**                              0                                     8                         **0**                                                                                  25      1169    **2**    0       326     **0**
  **Signs and symptoms--systemic:**                                                                                                                                                                                                                                                                                                               
  Fever                               614                                  639                                 **96**                             119                                   123                       **97**                              920     1005    **92**   103     131     **79**    4490    4800    **94**   673     688     **98**
  High grade fever                    3                                    13                                  **23**                             72                                    72                        **100**                             204     438     **47**                             2085    3178    **66**   68      126     **54**
  Relative bradycardia                77                                   271                                 **28**                             2                                     96                        **2**                               285     573     **50**   12      150     **8**     21      482     **4**    40      258     **16**
  Headache                            115                                  481                                 **24**                             64                                    123                       **52**                              374     909     **41**   73      131     **56**    425     3730    **11**   209     609     **34**
  Toxicity                            1                                    71                                  **1**                                                                                                                                  198     378     **52**   8       71      **11**    1072    3486    **31**   83      231     **36**
  Rash or rose spots                  97                                   523                                 **19**                             6                                     104                       **6**                               1       792     **0**    9       221     **4**     7       960     **1**    38      542     **7**
  Dehydration                         31                                   111                                 **28**                             3                                     24                        **13**                              66      278     **24**   22      71      **31**    3       50      **6**    18      167     **11**
  Coated tongue                                                                                                                                                                                                                                                                81      150     **54**    314     608     **52**   140     195     **72**
  **Respiratory and abdominal:**                                                                                                                                                                                                                                                                                                                  
  Cough                               122                                  434                                 **28**                             23                                    96                        **24**                              146     426     **34**   149     281     **53**    530     2823    **19**   263     786     **33**
  Nausea or vomiting                  229                                  582                                 **39**                             16                                    51                        **31**                              211     535     **39**   33      71      **46**    1634    4556    **36**   287     684     **42**
  Diarrhea                            269                                  609                                 **44**                             26                                    51                        **51**                              592     1161    **51**   43      131     **33**    1335    4503    **30**   308     922     **33**
  Constipation                        73                                   383                                 **19**                             3                                     24                        **13**                              61      324     **19**   0       0                 254     3895    **7**    240     772     **31**
  Hepatomegaly                        145                                  414                                 **35**                             79                                    123                       **64**                              103     405     **25**   62      131     **47**    2060    4510    **46**   545     801     **68**
  Splenomegaly                        168                                  512                                 **33**                             55                                    123                       **45**                              153     555     **28**   195     281     **69**    1441    4714    **31**   239     989     **24**
  Abdominal pain tenderness           215                                  555                                 **39**                             20                                    51                        **39**                              420     975     **43**   77      131     **59**    978     3782    **26**   385     786     **49**
  Abdominal distention or ileus       20                                   206                                 **10**                             9                                     51                        **18**                              236     809     **29**   103     221     **47**    254     4097    **6**    198     732     **27**
  **Laboratory features:**                                                                                                                                                                                                                                                                                                                        
  Anaemia (Hb \<12 g/dl)              78                                   209                                 **37**                             11                                    25                        **44**                              410     936     **44**   16      62      **26**    2284    3132    **73**   191     566     **34**
  Leukopenia (\<5 × 10^3^/µL)         84                                   408                                 **21**                             16                                    49                        **33**                              89      365     **24**   12      69      **17**    204     2069    **10**   213     653     **33**
  Leukocytosis (\>15 × 10^3^/µL)      1                                    41                                  **2**                              3                                     49                        **6**                               14      113     **12**   11      69      **16**    384     1754    **22**   12      177     **7**
  **Complications:**                                                                                                                                                                                                                                                                                                                              
  Shock or hypotension                2                                    50                                  **4**                                                                                                                                  4       131     **3**    4       71      **6**     123     2606    **5**    10      278     **4**
  Altered mental status               51                                   417                                 **12**                             44                                    123                       **36**                              155     1127    **14**                             414     4928    **8**    191     786     **24**
  Pneumonia or chest signs            19                                   305                                 **6**                              1                                     24                        **4**                               267     993     **27**   66      150     **44**    227     1966    **12**   66      785     **8**
  GI bleeding                         19                                   548                                 **3**                              2                                     24                        **8**                               37      1069    **3**    1       150     **1**     82      1385    **6**    24      616     **4**
  GI perforation                      4                                    449                                 **1**                                                                                                                                  63      996     **6**    1       150     **1**     13      943     **1**    3       274     **1**
  **Outcome:**                                                                                                                                                                                                                                                                                                                                    
  Relapse                             34                                   560                                 **6**                              4                                     58                        **7**                               34      938     **4**    18      210     **9**     194     3614    **5**    7       326     **2**
  Death                               5                                    567                                 **1**                              5                                     131                       **4**                               79      1328    **6**    10      210     **5**     83      4981    **2**    7       922     **1**

n -- number with feature, N -- number assessed

In comparing Africa (Sub Saharan Africa and Middle East/ North Africa) to South Asia, significant findings more likely to occur in children from African countries are presented in Table S6 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**.

Hospital vs community--based studies in children
------------------------------------------------

Data was derived from 83 prospective or retrospective studies or treatment trials of hospitalized, predominantly inpatient children from urban areas ([**Table 3**](#T3){ref-type="table"} and Table S7 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**). Data meeting the pre--defined criteria was scarce other than from hospital based studies, and could be extracted from only 6 studies conducted in community settings or health centers (outpatient) on children. Hospitalized children (Table S8 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**) presented most commonly with high--grade fever (odds ratio (OR) 4.7, 95% confidence interval (CI) 3.5--6.4), hepatomegaly (OR 7.1, 95% CI 4.2--12.0), nausea/vomiting (OR 2.0, 95% CI 1.6--2.6), abdominal distension (OR 7.4,95% CI 2.7--20.0), and coated tongue, anaemia and neutrophilia. Diarrhea (OR 5.2, 95% CI 3.8--7.2) and constipation (OR 4.2, 95% CI 1.9--9.6) were also associated more in hospitalized children. Other findings more likely to occur in hospitalized children were splenomegaly (OR 2.7, 95% CI 1.7--4.0); GI bleeding (OR 9.0, 95% CI 1.2--64.4); pre--treatment antibiotics received (OR 2.8, 95% CI 2.0--4.0) and duration of illness ≤1week (OR 1.8, 95% CI 1.3--2.4). Rose spots were an uncommon finding (5%). In all of the isolates reported in these studies, MDR was higher in hospitalized children compared to community based studies (OR 1.7, 95% CI 1.3--2.1).The most common complications in hospitalized children was DIC (18%), followed by pneumonia, arthritis/arthralgia, altered mental status, hepatitis, and meningitis (8--15%).

###### 

Enteric fever in children in hospital--based vs community/health--center (references to studies in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**)

                                        Hospital--based (83 studies)   Community--based or health center (out--patients) (6 studies)                            
  ------------------------------------- ------------------------------ --------------------------------------------------------------- -------- ------- ------- ---------
                                        **n**                          **N**                                                           **%**    **n**   **N**   **%**
  **Demographics/history:**                                                                                                                                     
  Blood/bone marrow isolates            7693                           8786                                                            **88**   407     407     **100**
  Pre--treatment antibiotics received   2047                           3709                                                            **55**   43      141     **30**
  Duration of illness ≤1week            1520                           3034                                                            **50**   69      193     **36**
  Multi--drug resistant isolates        2018                           4856                                                            **42**   93      313     **30**
  Fluoroquinolone resistance            11                             1433                                                            **1**    9       44      **20**
  **Signs and symptoms--systemic:**                                                                                                                             
  Fever                                 6327                           6787                                                            **93**   394     395     **100**
  High grade fever                      2372                           3622                                                            **65**   60      209     **29**
  Bradycardia or relative bradycardia   437                            1830                                                            **24**                   
  Headache                              1088                           5577                                                            **20**   169     368     **46**
  Toxicity                              1338                           4171                                                            **32**   18      28      **64**
  Rash or rose spots                    158                            3142                                                            **5**                    
  Dehydration                           143                            701                                                             **20**                   
  Coated tongue                         535                            953                                                             **56**                   
  **Respiratory and abdominal:**                                                                                                                                
  Cough                                 1153                           4588                                                            **25**   62      190     **33**
  Nausea or vomiting                    2300                           6038                                                            **38**   95      407     **23**
  Diarrhea                              2512                           6886                                                            **36**   42      423     **10**
  Constipation                          625                            5209                                                            **12**   6       193     **3**
  Hepatomegaly                          2946                           6175                                                            **48**   16      141     **11**
  Splenomegaly                          2193                           6937                                                            **32**   25      169     **15**
  Abdominal pain or tenderness          1901                           5873                                                            **32**   186     369     **50**
  Abdominal distention or ileus         814                            5889                                                            **14**   4       189     **2**
  **Laboratory features:**                                                                                                                                      
  Anaemia (Hb \<12 g/dL)                2976                           4908                                                            **61**                   
  Leukopenia (\<5 × 10^3^/µL)           602                            3442                                                            **17**   15      137     **11**
  Leukocytosis (\>15 × 10^3^/µL)        399                            2033                                                            **20**   17      136     **13**
  **Complications:**                                                                                                                                            
  Shock or hypotension                  143                            3136                                                            **5**                    
  Altered mental status                 853                            7343                                                            **12**                   
  Pneumonia or chest signs              647                            4232                                                            **15**                   
  GI bleeding                           164                            3603                                                            **5**    1       189     **1**
  GI perforation                        84                             2812                                                            **3**                    
  **Outcome:**                                                                                                                                                  
  Relapse                               291                            5706                                                            **5**                    
  Death                                 181                            7909                                                            **2**    0       209     **0**

n -- number with feature, N -- number assessed, Hb -- hemoglobin, GI -- gastrointestinal

MDR vs sensitive isolates in children
-------------------------------------

Thirty six studies provided either disaggregated data for MDR and drug sensitive enteric fever or had all sensitive or all MDR isolates ([**Table 4**](#T4){ref-type="table"} and Table S9 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**). Children infected with MDR isolates (sample size range from 11 to 1647) (Table S10 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**) presented late (duration of illness \>1week) (OR 2.7, 95% CI 2.1--3.4) with prior antibiotic treatment. Children infected with MDR strains were more toxic (OR 2.1, CI 1.6--2.6) and had relatively higher frequency of complications and adverse outcomes. Complications such as abdominal distention or ileus (OR 2.6, 95% CI 1.7--4.1), GI bleeding (OR 2.3, 95% CI 1.1--4.5), shock/hypotension (OR 2.9, 95% CI 1.2--7.3); myocarditis (OR 4.2, 95% CI 1.4--12.5) and pneumonia (OR 2.2, 95% CI 1.3--3.7) were higher in cases of MDR isolates compared to pan--sensitive isolates. High grade fever (OR 0.6, 95% CI 0.5--0.8), relapse (OR 0.3, 95% CI 0.1--0.7); leucopenia (OR 0.5, 95% CI 0.3--0.8); thrombocytopenia (OR 0.1, 95% CI 0.03--0.4) and arthritis or arthralgia/myalgia (OR 0.05,95% CI 0.01--0.4) were more frequent in children with sensitive isolates (sample size range from 13 to 2531). The case fatality was 1.0% vs 1.3% in resistant and sensitive enteric respectively.

###### 

Demographic and clinical features of enteric fever in children with multi--drug resistant vs sensitive strains of *S. typhi* and *S. paratyphi* (references to studies in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**)

                                        Multi--drug resistant (14 studies)   Sensitive (22 studies)                             
  ------------------------------------- ------------------------------------ ------------------------ --------- ------- ------- ---------
                                        **n**                                **N**                    **%**     **n**   **N**   **%**
  **Demographics/history:**                                                                                                     
  Multi--drug resistant isolates        1647                                 1647                     **100**   0       2531    **0**
  Chloramphenicol resistance            125                                  125                      **100**   9       293     **3**
  Fluoroquinolone resistance            0                                    183                      **0**     5       55      **9**
  Blood/bone marrow Isolates            1121                                 1121                     **100**   1600    1616    **99**
  Pre--treatment antibiotics received   10                                   11                       **91**    71      335     **21**
  Duration of illness ≤1week            151                                  417                      **36**    627     1034    **61**
  **Signs and symptoms--systemic:**                                                                                             
  Fever                                 620                                  653                      **95**    1350    1393    **97**
  High grade fever                      441                                  552                      **80**    945     1090    **87**
  Bradycardia or relative bradycardia   7                                    62                       **11**    3       218     **1**
  Headache                              116                                  220                      **53**    122     382     **32**
  Toxicity                              208                                  427                      **49**    316     1006    **31**
  Rash or rose spots                    3                                    153                      **2**     11      292     **4**
  Dehydration                           6                                    15                       **40**    11      190     **6**
  Coated tongue                         34                                   77                       **44**    8       13      **62**
  **Respiratory and abdominal:**                                                                                                
  Cough                                 92                                   256                      **36**    151     487     **31**
  Nausea or vomiting                    140                                  332                      **42**    128     371     **35**
  Diarrhea                              201                                  638                      **32**    464     1358    **34**
  Constipation                          52                                   487                      **11**    137     1203    **11**
  Hepatomegaly                          456                                  725                      **63**    699     1639    **43**
  Splenomegaly                          320                                  694                      **46**    433     1669    **26**
  Abdominal pain or tenderness          294                                  600                      **49**    358     1259    **28**
  Abdominal distention or ileus         55                                   260                      **21**    40      434     **9**
  **Laboratory features:**                                                                                                      
  Anaemia (Hb \<12 g/dL)                296                                  442                      **67**    656     1170    **56**
  Leukopenia (\<5 × 10^3^/µL)           20                                   362                      **6**     132     1177    **11**
  Leukocytosis (\>15 × 10^3^/µL)        80                                   300                      **27**    231     914     **25**
  **Complications:**                                                                                                            
  Shock or hypotension                  20                                   115                      **17**    7       105     **7**
  Altered mental status                 80                                   586                      **14**    83      638     **13**
  Pneumonia or chest signs              32                                   219                      **15**    35      484     **7**
  GI bleeding                           28                                   382                      **7**     12      357     **3**
  GI perforation                        4                                    142                      **3**     1       136     **1**
  **Outcome:**                                                                                                                  
  Relapse                               7                                    329                      **2**     12      151     **8**
  Death                                 23                                   1647                     **1.0**   31      2339    **1.3**

n -- number with feature, N -- number assessed

Other significant features more likely to be seen in MDR cases are shown in Table S10 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**.

DISCUSSION
==========

Despite advances in public health and hygiene that have led to a disappearance of enteric fever from much of the developed world, it still remains the commonest bacteraemic illness in South Asian countries with children being especially susceptible \[[@R1],[@R14]\]. The emergence of multi--drug resistance is very concerning due to the limited therapeutic options, high financial implications and its continuing burden in impoverished, low--income countries \[[@R6],[@R14],[@R21]\].

Several limitations should be recognized in considering our data. Our inclusion of culture proven and serological confirmed cases with culture confirmation in at least 50% of these cases may not reflect the true clinical features profile of enteric fever. With the high prevalence of prior antibiotic treatment, culture proven diagnosis may have been falsely low. On the contrary, exclusion of clinically diagnosed cases may also have resulted in missing out enteric fever with atypical features. An overwhelming majority of included studies were from urban areas, with many studies from rural areas excluded for reasons such as mixed reporting of adults and children, or diagnosis solely on clinical features ([**Box 1**](#B1){ref-type="boxed-text"}). Many community level studies were also excluded due to similar reasons. Existing literature gives a varying, non--standardized representation of enteric fever since there are differences in definitions such as adult/pediatric age group cutoffs, relapse, altered mental status and other clinical features. Case series (such as "all complicated cases excluded", or "all with diarrhea") were excluded as well. Paratyphoid fever was not included to be reviewed in this systematic review as it has a different clinical spectrum, however in 28% of cases data could not be separated from typhoid fever.

Outcomes such as resistance, relapse, and mortality were not reported in all studies, leading to an incomplete representation. Confounders, such as co--morbidities, resistance, socio--economic status, heterogeneous access to health could not be adjusted for since individual level data were not analyzed. Current trends in resistance especially nalidixic acid resistance and emerging fluoroquinolone resistance have not been extensively reported. Most studies were from South Asia, especially India and Pakistan. Regions were categorized based on the World Bank list of economies, which gives geographic classifications for low--income and middle--income economies only, while high income countries that may reflect any geographical region with an improved developmental status. Furthermore, our review is not fully representative of non--English language speaking regions of the world, although data from translated abstracts were used where possible.

Notwithstanding the above, our review highlights a number of key findings of the epidemiological pattern of enteric fever in different categories, which will assist the clinician in his diagnosis and help in the fight against enteric fever. Most of our data are from urban, hospitalized children who were more likely to have the following features: high--grade fever, nausea/vomiting, diarrhea, constipation, hepatomegaly, splenomegaly, neutrophilia, abdominal distension and GI bleeding. Young children (under 5 years) were more likely to show anaemia, diarrhea, leukocytosis, hepatitis and hepatomegaly and had a higher mortality. Older children commonly showed an altered mental status, signs of URTI leucopenia, and abdominal pain/tenderness. Adults were more likely to present with splenomegaly, GI perforation, and thrombocytopenia.

In previous literature, the commonest complications are reported to be gastrointestinal bleeding, intestinal perforation, encephalopathy and shock \[[@R5],[@R14],[@R33]\], though our review suggests that DIC, pneumonia, arthritis/arthralgia altered mental status, hepatitis, and meningitis predominate. The high frequency of DIC in our review was determined from 4 studies with one study forming the majority of the data \[[@R17]\]. Of note, the 'classic' stepladder temperature pattern \[[@R34]\] was only present in 25% of adult patients. Amongst children in the preschool years, a high case--fatality rate of 6% was found from the included studies, and death was 4.5 times more likely to occur compared to school--aged children. One included study had a particularly strong association of mortality in younger children with anaemia \[[@R17]\]. This high mortality and high incidence \[[@R25],[@R35]\] identifies this age group as a high risk group to be addressed for vaccinations.

Other related or underlying factors influencing the clinical profile and outcomes of enteric fever are varying strain virulence, inoculum size, delays in or duration of treatment received, numerous host factors such as immune response, co--existing illnesses or infections, or underlying malnutrition \[[@R5],[@R12],[@R36]\]. These findings must be considered with caution, as our review was limited to studies with full reporting of clinical features and many studies with only outcome data were excluded. Others have recently reported increased disease severity with emergence of fluoroquinolone resistance \[[@R37]\].

There is insufficient and inconsistent reporting of clinical features data in MDR isolates, especially in the 1980s when the first few outbreaks were reported \[[@R5]\]. This may be due to a publication bias, since chloramphenicol resistance data was being reported at 10% from that time period \[[@R5]\].The complications are higher with multi--drug resistant strains and these isolates have been shown to be more virulent than sensitive strains \[[@R38],[@R39]\].In this review, the case--fatality rates from all resistant and all sensitive *S. typhi* were almost the same (1.0% in MDR strains vs 1.3% in sensitive strains), reflecting a general decrease in overall mortality in treated cases since the advent of antibiotic usage and improved health care, as our review is mostly derived from inpatient reports (77% of studies).

The case fatality rate of 2% from 83 studies in hospitalized children, is comparable to case--fatality rates reviewed by Crump et al. \[[@R18]\] from 10 population--based studies (although in mixed age groups) which showed a range of 0--1.8%. However, regionally, Sub--Saharan Africa, and North Africa and Middle East had the highest case--fatality rates (5--6%). The relapse rate was low, ranging from 2--9% in all regions, reflecting improved hospital care and initiation of antibiotics, while regional differences in case--fatality rate ranged from 1--6%, highest in Sub Saharan Africa and North Africa/Middle East regions. This may reflect the higher rate of complications such as GI perforation, GI bleed and pneumonia in these regions. As this data spans studies prior to the onset of improved health care access and surgical treatments, as well as after it reflects the overall picture of mortality enteric fever has posed on each region.

Widespread antibiotic pre--treatment was present in all regions, except Europe and Central Asia, due to prevalence of self--medication and poor health--seeking behaviors \[[@R40]\]. This has implications for the development of newer diagnostic tests that can replace blood culture, and ideally be more rapid, specific and cost-effective as well as sensitive. Rational use of antibiotics based on culture sensitivity patterns in different regions in imperative in curtailing the further evolution of multi--drug resistance which is already rife.

Applicability and implications for research
-------------------------------------------

Although enteric fever is essentially a pediatric disease in South Asia, there is a serious dearth of data from children in community settings in global literature \[[@R3],[@R23],[@R25],[@R41]-[@R43]\]. Hospital--based data helps show severity of infection and outcomes associated with treatment, but capturing data on clinical features from studies based in the community is imperative to strengthen our ability to pick and treat enteric fever in the most vulnerable and to better understand presentation of drug resistance and treatment outcomes of mild enteric fever. Treatment requires a low threshold for empirical antibiotics but this must be weighed against the growing rates of resistance in many regions that make treatment options complex and costly. The solution will have to be multi--faceted and include improved sanitation, vaccination implementation in high--risk populations in combination with rapid diagnosis, elimination of carriers, and rational use of the antibiotic options. Vaccinations as part of national immunizations programs (EPI) for those under 2 years of age in high risk populations will have to be the key in restriction of the spread of disease through reducing both disease transmission and new carriers, until water and sanitation are universally upgraded \[[@R33],[@R44],[@R45]\].

Future studies should be designed keeping these gaps in mind and focus on community based enteric cases. Descriptions of all clinical features, resistance patterns and mortality should be a primary objective of researchers in treatment trials, vaccine trials and prospective/retrospective studies, preferably in separate cohorts based on age (children vs adults), using standardized, clearly defined age categories. The cut--offs for MIC for fluoroquinolones have been recently revised and reports should include references of the MIC used by their laboratory. There is a need for randomized control trials for appropriate outpatient therapy in the face of rising resistance to commonly used antimicrobials.

Surveillance networks
---------------------

There is a need to establish a consortium for reporting of enteric fever, especially with regard to AMR (antimicrobial resistance) as well as a central repository for genomic studies, looking at SNP related to enteric severity. The Coalition Against Typhoid \[[@R46]\] for example, is a global forum of health and immunization experts working to expedite and sustain evidence--based decisions at the global, regional and national levels regarding the use of enteric vaccination to prevent childhood enteric fever. They state the need to develop long and short term goals for enteric control, which include for the short term high burden and at risk populations immunizations, good hygiene practices, and for long term improvements in access to safe water and improved sanitation as their goals.
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